BlossomHill Therapeutics Inc., a San Diego biotech focused on precision cancer treatments, has filed registration paperwork with the SEC to launch an IPO, aiming to raise approximately $132.8 million by offering 7.8 million shares priced between $15 and $17 each. Established in 2020, the company plans to use the proceeds to fund clinical development of its two early-stage therapies, as it has yet to generate revenue from an approved drug. Despite recent increased investor confidence in biotech, BlossomHill posted a net loss of $21 million for Q1 2026, highlighting the financial challenges faced by clinical-stage firms. The IPO is seen as a critical test of market appetite for cancer drug development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.briefs.co/news/san-diego-cancer-biotech-blossomhill-seeks-public-listing-to/
